
Commentary|Videos|July 22, 2025
Integrating Luspatercept Into Clinical Practice and Community Settings in ESA-Naive Lower-Risk MDS
Author(s)Guillermo Garcia-Manero, MD
Fact checked by: Chris Ryan
Guillermo Garcia-Manero, MD, discusses the integration of luspatercept into real-world practice in ESA-naive, lower-risk MDS.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5

